ijms-logo

Journal Browser

Journal Browser

Gynecological Cancer: Targeted Therapeutics and Future Perspectives

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 15 June 2024 | Viewed by 1500

Special Issue Editor


E-Mail Website
Guest Editor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
Interests: gynecological neoplasms; breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is well-known that gynecological cancers represent a real global public health problem. Moreover, their worldwide incidence and mortality rates are rising yearly, supporting the idea that therapeutical strategies and screening programs must be urgently revised and improved. This Special Issue aims to shed light on the recent advances in understanding the molecular background of gynecological cancer using significant genomic assays. The international guidelines promote a histomolecular approach to perform more accurate prognostic risk stratification and open the way to discovering and experimenting with more innovative targeted therapeutics. In this way,  the present research topic will provide a comprehensive review of the molecular alterations and the clinical evidence of ongoing and ended clinical trials on gynecological cancer and discuss the future implications of innovative molecular diagnostic and therapeutical approaches.

Since IJMS is a journal of molecular science, pure clinical studies will not suitable, but clinical submissions with biomolecular experiments are welcomed.

Dr. Angela Santoro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  •  molecular background
  •  precision medicine
  •  histomolecular diagnosis
  •  targeted therapies
  •  clinical trials
  •  overall survival
  •  disease-free survival
  •  gynecological cancer
  •  whole genomic assay
  •  molecular biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 3185 KiB  
Review
Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications
by Francesca Addante, Antonio d’Amati, Angela Santoro, Giuseppe Angelico, Frediano Inzani, Damiano Arciuolo, Antonio Travaglino, Antonio Raffone, Nicoletta D’Alessandris, Giulia Scaglione, Michele Valente, Giordana Tinnirello, Stefania Sfregola, Belen Padial Urtueta, Alessia Piermattei, Federica Cianfrini, Antonino Mulè, Emma Bragantini and Gian Franco Zannoni
Int. J. Mol. Sci. 2024, 25(2), 1056; https://doi.org/10.3390/ijms25021056 - 15 Jan 2024
Cited by 2 | Viewed by 1264
Abstract
Among the four endometrial cancer (EC) TCGA molecular groups, the MSI/hypermutated group represents an important percentage of tumors (30%), including different histotypes, and generally confers an intermediate prognosis for affected women, also providing new immunotherapeutic strategies. Immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6 [...] Read more.
Among the four endometrial cancer (EC) TCGA molecular groups, the MSI/hypermutated group represents an important percentage of tumors (30%), including different histotypes, and generally confers an intermediate prognosis for affected women, also providing new immunotherapeutic strategies. Immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6 and PMS2) has become the optimal diagnostic MSI surrogate worldwide. This review aims to provide state-of-the-art knowledge on MMR deficiency/MSI in EC and to clarify the pathological assessment, interpretation pitfalls and reporting of MMR status. Full article
(This article belongs to the Special Issue Gynecological Cancer: Targeted Therapeutics and Future Perspectives)
Show Figures

Figure 1

Back to TopTop